KR20010092772A - 석회화된 조직을 표적으로 하는, 통증 완화, 뼈 암 치료,및 뼈 표면 조절용 라듐-223의 제조 및 용도 - Google Patents
석회화된 조직을 표적으로 하는, 통증 완화, 뼈 암 치료,및 뼈 표면 조절용 라듐-223의 제조 및 용도 Download PDFInfo
- Publication number
- KR20010092772A KR20010092772A KR1020017008497A KR20017008497A KR20010092772A KR 20010092772 A KR20010092772 A KR 20010092772A KR 1020017008497 A KR1020017008497 A KR 1020017008497A KR 20017008497 A KR20017008497 A KR 20017008497A KR 20010092772 A KR20010092772 A KR 20010092772A
- Authority
- KR
- South Korea
- Prior art keywords
- bone
- acid
- radium
- cancer
- liquid
- Prior art date
Links
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 75
- HCWPIIXVSYCSAN-OIOBTWANSA-N radium-223 Chemical compound [223Ra] HCWPIIXVSYCSAN-OIOBTWANSA-N 0.000 title claims abstract description 28
- 229960005562 radium-223 Drugs 0.000 title claims abstract description 26
- 208000018084 Bone neoplasm Diseases 0.000 title claims abstract description 9
- 206010005949 Bone cancer Diseases 0.000 title claims description 7
- 238000002360 preparation method Methods 0.000 title claims description 6
- 210000001519 tissue Anatomy 0.000 title description 11
- 230000003750 conditioning effect Effects 0.000 title 1
- 238000011275 oncology therapy Methods 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 26
- 210000004872 soft tissue Anatomy 0.000 claims abstract description 15
- 238000011282 treatment Methods 0.000 claims abstract description 14
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 13
- 239000007788 liquid Substances 0.000 claims description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 17
- 239000000243 solution Substances 0.000 claims description 17
- 239000011347 resin Substances 0.000 claims description 15
- 229920005989 resin Polymers 0.000 claims description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 12
- 238000009472 formulation Methods 0.000 claims description 11
- 229940121896 radiopharmaceutical Drugs 0.000 claims description 11
- 239000012217 radiopharmaceutical Substances 0.000 claims description 11
- 230000002799 radiopharmaceutical effect Effects 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 10
- 230000003211 malignant effect Effects 0.000 claims description 10
- 230000005855 radiation Effects 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 9
- -1 inorganic acid salt Chemical class 0.000 claims description 9
- 150000001768 cations Chemical class 0.000 claims description 8
- 150000007522 mineralic acids Chemical class 0.000 claims description 8
- 239000000758 substrate Substances 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 7
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 7
- 238000001556 precipitation Methods 0.000 claims description 7
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 6
- 239000000084 colloidal system Substances 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 6
- 239000000377 silicon dioxide Substances 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 150000001735 carboxylic acids Chemical class 0.000 claims description 5
- 239000000969 carrier Substances 0.000 claims description 5
- MBKDYNNUVRNNRF-UHFFFAOYSA-N medronic acid Chemical class OP(O)(=O)CP(O)(O)=O MBKDYNNUVRNNRF-UHFFFAOYSA-N 0.000 claims description 5
- 239000012071 phase Substances 0.000 claims description 5
- 238000012546 transfer Methods 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 4
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 229910017604 nitric acid Inorganic materials 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 229940122361 Bisphosphonate Drugs 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 239000008346 aqueous phase Substances 0.000 claims description 3
- 150000004663 bisphosphonates Chemical class 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- DTIFKFQAKZWSGE-UHFFFAOYSA-N P(O)(O)=O.P(O)(O)=O.C(C)C(CC)CCCC Chemical compound P(O)(O)=O.P(O)(O)=O.C(C)C(CC)CCCC DTIFKFQAKZWSGE-UHFFFAOYSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 2
- 238000002648 combination therapy Methods 0.000 claims description 2
- 238000011161 development Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000037406 food intake Effects 0.000 claims description 2
- 238000001794 hormone therapy Methods 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 238000011068 loading method Methods 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 238000006386 neutralization reaction Methods 0.000 claims description 2
- 235000006408 oxalic acid Nutrition 0.000 claims description 2
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 claims description 2
- 229910052712 strontium Inorganic materials 0.000 claims description 2
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- XTRCZGGLPJAMGQ-UHFFFAOYSA-N 9-phosphonoheptadecan-9-ylphosphonic acid Chemical compound CCCCCCCCC(P(O)(O)=O)(P(O)(O)=O)CCCCCCCC XTRCZGGLPJAMGQ-UHFFFAOYSA-N 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- 239000002245 particle Substances 0.000 description 11
- SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical compound [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 206010027476 Metastases Diseases 0.000 description 7
- 210000001185 bone marrow Anatomy 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 229910052705 radium Inorganic materials 0.000 description 7
- 229910052704 radon Inorganic materials 0.000 description 7
- HCWPIIXVSYCSAN-UHFFFAOYSA-N radium atom Chemical compound [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- 239000012086 standard solution Substances 0.000 description 5
- 206010033799 Paralysis Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 210000000689 upper leg Anatomy 0.000 description 4
- HCWPIIXVSYCSAN-IGMARMGPSA-N Radium-226 Chemical compound [226Ra] HCWPIIXVSYCSAN-IGMARMGPSA-N 0.000 description 3
- JCXGWMGPZLAOME-AKLPVKDBSA-N bismuth-212 Chemical compound [212Bi] JCXGWMGPZLAOME-AKLPVKDBSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 210000002805 bone matrix Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- NFDRPXJGHKJRLJ-UHFFFAOYSA-N edtmp Chemical compound OP(O)(=O)CN(CP(O)(O)=O)CCN(CP(O)(O)=O)CP(O)(O)=O NFDRPXJGHKJRLJ-UHFFFAOYSA-N 0.000 description 3
- 238000001730 gamma-ray spectroscopy Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- HCWPIIXVSYCSAN-YPZZEJLDSA-N radium-224 Chemical compound [224Ra] HCWPIIXVSYCSAN-YPZZEJLDSA-N 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229910052767 actinium Inorganic materials 0.000 description 2
- QQINRWTZWGJFDB-UHFFFAOYSA-N actinium atom Chemical compound [Ac] QQINRWTZWGJFDB-UHFFFAOYSA-N 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- JCXGWMGPZLAOME-NJFSPNSNSA-N bismuth-211 Chemical compound [211Bi] JCXGWMGPZLAOME-NJFSPNSNSA-N 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- PSFDQSOCUJVVGF-UHFFFAOYSA-N harman Chemical compound C12=CC=CC=C2NC2=C1C=CN=C2C PSFDQSOCUJVVGF-UHFFFAOYSA-N 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- WABPQHHGFIMREM-RNFDNDRNSA-N lead-211 Chemical compound [211Pb] WABPQHHGFIMREM-RNFDNDRNSA-N 0.000 description 2
- WABPQHHGFIMREM-BKFZFHPZSA-N lead-212 Chemical compound [212Pb] WABPQHHGFIMREM-BKFZFHPZSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000003608 radiolysis reaction Methods 0.000 description 2
- SYUHGPGVQRZVTB-OIOBTWANSA-N radon-219 atom Chemical compound [219Rn] SYUHGPGVQRZVTB-OIOBTWANSA-N 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 229940006509 strontium-89 Drugs 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- QBPPRVHXOZRESW-UHFFFAOYSA-N 1,4,7,10-tetraazacyclododecane Chemical compound C1CNCCNCCNCCN1 QBPPRVHXOZRESW-UHFFFAOYSA-N 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 206010027452 Metastases to bone Diseases 0.000 description 1
- 229940127048 Metastron Drugs 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- JSTADIGKFYFAIY-GJNDDOAHSA-K [2-[bis[[hydroxy(oxido)phosphoryl]methyl]amino]ethyl-(phosphonomethyl)amino]methyl-hydroxyphosphinate;samarium-153(3+) Chemical compound [H+].[H+].[H+].[H+].[H+].[153Sm+3].[O-]P([O-])(=O)CN(CP([O-])([O-])=O)CCN(CP([O-])([O-])=O)CP([O-])([O-])=O JSTADIGKFYFAIY-GJNDDOAHSA-K 0.000 description 1
- RCXMQNIDOFXYDO-UHFFFAOYSA-N [4,7,10-tris(phosphonomethyl)-1,4,7,10-tetrazacyclododec-1-yl]methylphosphonic acid Chemical compound OP(O)(=O)CN1CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CC1 RCXMQNIDOFXYDO-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229910052768 actinide Inorganic materials 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 230000005262 alpha decay Effects 0.000 description 1
- LBDSXVIYZYSRII-IGMARMGPSA-N alpha-particle Chemical compound [4He+2] LBDSXVIYZYSRII-IGMARMGPSA-N 0.000 description 1
- 238000001280 alpha-particle spectroscopy Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- JCXGWMGPZLAOME-RNFDNDRNSA-N bismuth-213 Chemical compound [213Bi] JCXGWMGPZLAOME-RNFDNDRNSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011347 external beam therapy Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 208000010726 hind limb paralysis Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229910052756 noble gas Inorganic materials 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005258 radioactive decay Effects 0.000 description 1
- 150000003255 radium Chemical class 0.000 description 1
- 229940006475 radium cation Drugs 0.000 description 1
- SYUHGPGVQRZVTB-YPZZEJLDSA-N radon-220 atom Chemical compound [220Rn] SYUHGPGVQRZVTB-YPZZEJLDSA-N 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000001413 spine osteoarthritis Diseases 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- CIOAGBVUUVVLOB-OUBTZVSYSA-N strontium-89 Chemical compound [89Sr] CIOAGBVUUVVLOB-OUBTZVSYSA-N 0.000 description 1
- AHBGXTDRMVNFER-FCHARDOESA-L strontium-89(2+);dichloride Chemical compound [Cl-].[Cl-].[89Sr+2] AHBGXTDRMVNFER-FCHARDOESA-L 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000013077 target material Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Biological Depolymerization Polymers (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Materials For Medical Uses (AREA)
- Compounds Of Unknown Constitution (AREA)
- Physical Or Chemical Processes And Apparatus (AREA)
- Radiation-Therapy Devices (AREA)
Abstract
Description
핵종 | 223Ra | 219Rn | 215Po | 211Pb | 211Bi | 207Tl |
α-에너지 | 5.64 MeV | 6.75 MeV | 7.39 MeV | 6.55 MeV | ||
β-에너지(최대) | 0.47 MeV | 0.47 MeV | ||||
에너지 분율# | 0.207 | 0.248 | 0.271 | ≤0.017 | 0.24 | ≤0.017 |
* Seelmann-Eggebert 등(1981) 및 Ekstroem 등(1989)로부터의 데이타# 완전 붕괴 사슬의 총 방출 에너지에 대한 상대값 |
조직 | 6 시간 | 3 일 |
대퇴골 | 25.86 ±1.99 | 34.55 ±7.87 |
혈액 | 0.20 ±0.23 | 0.05 ±0.10 |
신장 | 4.04 ±0.33 | 0.38 ±0.08 |
간 | 0.89 ±0.18 | 0.22 ±0.32 |
폐 | 0.59 ±0.56 | 0.06 ±0.07 |
근육 | 0.72 ±0.39 | 0.30 ±0.16 |
심장 | 0.10 ±0.10 | 0.06 ±0.07 |
뇌 | 0.04 ±0.01 | 0.12 ±0.12 |
비장 | 4.06 ±1.4 | 1.46 ±0.54 |
소장 | 0.79 ±0.26 | 0.04 ±0.03 |
대장 | 2.30 ±0.60 | 0.13 ±0.02 |
Claims (18)
- 무기 기질 상에 AC-수지를 함유하는 발생체 컬럼에 모핵종을 적재하는 것, 또는 액/액 추출 시스템에서 AC-수지를 이용하는 단계를 포함하는 것을 특징으로 하는, 생의학적 용도를 위한 라듐-223의 제조 방법.
- 제 1 항에 있어서, 상기 발생체 컬럼이 실리카 기질상에 메탄 비스-포스폰산 유도체를 함유하고, 액/액 추출 단계에서 1종 이상의 P,P' 디에스테르화된 메틸렌 비스-포스폰산 유도체 또는 이들의 혼합물을 상 전이제로 사용하는 것을 특징으로 하는 방법.
- 제 2 항에 있어서, 상기 발생체 컬럼이 실리카 기질 상에 P,P' 디-옥틸 메탄 비스-포스폰산을 함유하고, 액/액 추출 단계에서 P,P' 디-옥틸 메틸렌 비스-포스폰산 또는 P,P' 디(2-에틸헥실)메탄 비스-포스폰산 또는 이들의 혼합물을 상 전이제로 사용하는 것을 특징으로 하는 방법.
- 제 1 항 내지 제 3 항 중 어느 한 항에 있어서, 발생체 컬럼이, 중화 후 무기산 염의 생리학적으로 적합한 용액을 제공하는 무기산, 바람직하게는 질산 또는 염산을 함유하고, 액/액 추출 단계에서 무기산, 바람직하게는 질산 또는 염산으로 이루어진 수성상을 사용하는 것을 특징으로 하는 방법.
- 제 4 항에 있어서, 컬럼에서 무기산의 농도가 0.01M - 8M, 바람직하게는 0.1M - 2M, 더욱 바람직하게는 0.5M - 1M이고, 액/액 추출에서 무기산의 농도가 0.01M - 8M, 바람직하게는 0.1M - 2M, 더욱 바람직하게는 0.8M - 1.5M인 것을 특징으로 하는 방법.
- 생리학적으로 허용가능한 담체 및 보조약 외에, 용해된 라듐-223 염을 포함하고, 안정화 알칼리토 금속 양이온 유사체 담체로서의 단일 양이온 또는 여러 양이온의 조합이 있거나 없고, 콜로이드의 침전 및(또는) 발생을 막는 약제가 있거나 없는 것을 특징으로 하는, 생체내 투여를 위한 생리학적으로 허용가능한 제제.
- 제 6 항에 있어서, 안정화 알칼리토 금속 양이온으로 안정화시키는 작용을 하는 양이온이 마그네슘, 칼슘 및 스트론튬으로 이루어진 군으로부터 선택된 것인 것을 특징으로 하는 제제.
- 제 6 항 또는 제 7 항에 있어서, 콜로이드의 침전 및(또는) 발생을 막는 약제가 카르복실산 또는 카르복실산들의 조합인 것을 특징으로 하는 제제.
- 제 8 항에 있어서, 카르복실산이 옥살산, 옥살로아세트산, 타르타르산, 숙신산, 말산 및 말론산으로 이루어진 군으로부터 선택된 것인 것을 특징으로 하는 제제.
- 제 4 항 내지 제 6 항 중 어느 한 항에 있어서, 주사(injection), 주입 (infusion) 또는 섭취, 또는 이들의 조합용으로 제조된 것임을 특징으로 하는 제제.
- 뼈 및 뼈 표면의 질병의 치료에 약학적 활성을 갖는 제제를 제조하기 위한 라듐-223의 용도.
- 제 11 항에 있어서, 상기 제제를 치료적 활성을 갖는 또다른 성분, 예를 들면(이에 제한되지는 않음), 비스포스포네이트를 포함하는 화학요법, 외과수술, 외부 광선 조사, 저-LET 방사선 방출 뼈 탐색 방사성 약물, 및 호르몬 치료와의 결합 치료에 사용하는 용도.
- 제 11 항 또는 제12항에 있어서, 상기 제제를 뼈 및(또는) 연질 조직에 영향을 주는 비악성 및 악성 질병에 관련된 치료 및(또는) 완화에 사용하는 용도.
- 제 11 항 내지 제 13 항 중 어느 한 항에 있어서, 악성 질병이 전립선암, 유방암, 신장암 및 요암, 일차 뼈 암, 폐암 및 다발성 골수종으로 이루어진 군으로부터 선택된 것인 용도.
- 제 6 항 내지 제 10 항 중 어느 한 항에 따른 제제의 완화적 또는 치료적 효과량을 예방 또는 치료가 필요한 포유류에게 투여하는 단계를 포함하는, 포유류에서 뼈 및 연질 조직에 영향을 주는 비악성 또는 악성 질병의 예방 또는 치료 방법.
- 제 15 항에 있어서, 예방적 효과량을 포유류에게 투여하는 것을 특징으로 하는 방법.
- 제 14 항 내지 제 16 항 중 어느 한 항에 있어서, 포유류가 개 또는 인간인 것을 특징으로 하는 방법.
- 제 1 항 내지 제 5 항 중 어느 한 항에 따라 제조된223Ra, 제 7 항에 따른 안정화 알칼리토 금속 양이온 유사체 담체로서의 양이온, 및 제 8 항 또는 제 9 항에 따른, 콜로이드의 침전 및(또는) 발생을 막는 약제, 약학적으로 허용가능한 담체 및 적합한 투여 장치를 포함하는 것을 특징으로 하는 키트.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NO19990001 | 1999-01-04 | ||
NO990001A NO310544B1 (no) | 1999-01-04 | 1999-01-04 | Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20010092772A true KR20010092772A (ko) | 2001-10-26 |
KR100671387B1 KR100671387B1 (ko) | 2007-01-19 |
Family
ID=19902803
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020017008497A KR100671387B1 (ko) | 1999-01-04 | 1999-12-17 | 석회화된 조직을 표적으로 하는, 통증 완화, 뼈 암 치료,및 뼈 표면 조절용 라듐-223의 제조 및 용도 |
Country Status (25)
Country | Link |
---|---|
US (2) | US6635234B1 (ko) |
EP (1) | EP1140212B1 (ko) |
JP (2) | JP4649044B2 (ko) |
KR (1) | KR100671387B1 (ko) |
CN (2) | CN1194764C (ko) |
AT (1) | ATE331534T1 (ko) |
AU (1) | AU774991B2 (ko) |
BE (1) | BE2014C028I2 (ko) |
BR (1) | BR9916768A (ko) |
CA (1) | CA2358498C (ko) |
CY (2) | CY1105634T1 (ko) |
DE (1) | DE69932183T2 (ko) |
DK (1) | DK1140212T3 (ko) |
EA (1) | EA003496B1 (ko) |
ES (1) | ES2268888T3 (ko) |
HK (1) | HK1090750A1 (ko) |
IL (1) | IL144135A0 (ko) |
LU (1) | LU92425I2 (ko) |
MX (1) | MXPA01006823A (ko) |
NO (2) | NO310544B1 (ko) |
NZ (3) | NZ534618A (ko) |
PT (1) | PT1140212E (ko) |
TR (3) | TR200201442T2 (ko) |
WO (1) | WO2000040275A2 (ko) |
ZA (1) | ZA200105431B (ko) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO310544B1 (no) * | 1999-01-04 | 2001-07-23 | Algeta As | Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben |
NO314537B1 (no) * | 1999-12-06 | 2003-04-07 | Anticancer Therapeutic Inv Sa | Reseptorbindende konjugater |
NO313180B1 (no) | 2000-07-04 | 2002-08-26 | Anticancer Therapeutic Inv Sa | Bensökende alfapartikkel emitterende radiofarmasöytika |
AUPQ923100A0 (en) * | 2000-08-07 | 2000-08-31 | Peplin Research Pty Ltd | Treatment of prostate cancer |
JP4502641B2 (ja) * | 2002-01-24 | 2010-07-14 | ティルタン ファーマ リミテッド | 抗癌組み合わせおよびその使用方法 |
GB0213261D0 (en) * | 2002-06-10 | 2002-07-17 | Anticancer Therapeutic Inv Sa | Method |
GB0308731D0 (en) * | 2003-04-15 | 2003-05-21 | Anticancer Therapeutic Inv Sa | Method of radiotherapy |
KR101130187B1 (ko) * | 2003-04-30 | 2012-03-29 | 라모트 앳 텔-아비브 유니버시티 리미티드 | 방사선치료 방법 및 장치 |
AU2005215234B2 (en) * | 2004-02-20 | 2009-02-19 | Algeta As | Alpha-emitting Hydroxyapatite particles |
DE102004022200B4 (de) * | 2004-05-05 | 2006-07-20 | Actinium Pharmaceuticals, Inc. | Radium-Target sowie Verfahren zu seiner Herstellung |
US7914766B1 (en) * | 2004-06-03 | 2011-03-29 | Ut-Battelle Llc | Inorganic resins for clinical use of 213Bi generators |
GB0423565D0 (en) * | 2004-10-22 | 2004-11-24 | Algeta As | Formulation |
AU2006273680A1 (en) * | 2005-07-26 | 2007-02-01 | Ramot At Tel Aviv University Ltd. | A radioactive surface source and a method for producing the same |
US8709380B1 (en) * | 2006-02-07 | 2014-04-29 | Sirius Medicine, Llc | Targeting agents for enhancing radiation therapy |
DE102006008023B4 (de) * | 2006-02-21 | 2008-05-29 | Actinium Pharmaceuticals, Inc. | Verfahren zum Reinigen von 225Ac aus bestrahlten 226Ra-Targets |
ES2784662T3 (es) * | 2006-09-08 | 2020-09-29 | Actinium Pharmaceuticals Inc | Método para la purificación de radio a partir de diferentes fuentes |
EP2116539A1 (en) | 2008-04-25 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof |
EP2353598A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for use in the prevention and/or treatment of postoperative pain |
EP2353591A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof |
GB201002508D0 (en) | 2010-02-12 | 2010-03-31 | Algeta As | Product |
GB201007354D0 (en) * | 2010-04-30 | 2010-06-16 | Algeta Asa | Method |
GB201007353D0 (en) | 2010-04-30 | 2010-06-16 | Algeta Asa | Method |
EP2388005A1 (en) | 2010-05-21 | 2011-11-23 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy |
EP2415471A1 (en) | 2010-08-03 | 2012-02-08 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in opioid-induced hyperalgesia |
EP2524694A1 (en) | 2011-05-19 | 2012-11-21 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in diabetes type-2 associated pain |
EP2934545A1 (en) | 2012-12-19 | 2015-10-28 | Bayer Pharma Aktiengesellschaft | Combination comprising radium-223 for the treatment of cancer |
GB201314718D0 (en) * | 2013-08-16 | 2013-10-02 | Algeta As | Quantification method |
CA2932221C (en) | 2013-12-03 | 2022-02-22 | Bayer Pharma Aktiengesellschaft | Combination of pi3k-inhibitors |
WO2015082378A1 (en) | 2013-12-03 | 2015-06-11 | Bayer Pharma Aktiengesellschaft | Combination of pi3k-inhibitors |
TW201607538A (zh) | 2013-12-17 | 2016-03-01 | 以斯提夫博士實驗室股份有限公司 | 血清素-去甲腎上腺素再攝取抑制劑(SNRIS)和σ受體配體組合物 |
WO2016083739A1 (fr) | 2014-11-26 | 2016-06-02 | Rhodia Operations | Composition de lanthane et d'actinium-227 |
GB201600154D0 (en) * | 2016-01-05 | 2016-02-17 | Bayer As | Isotope preparation method |
GB201600153D0 (en) * | 2016-01-05 | 2016-02-17 | Bayer As | Isotope preparation method |
CZ2016821A3 (cs) * | 2016-12-22 | 2018-07-04 | České vysoké učení technické v Praze | Kombinace pro radionuklidovou terapii pro použití jako léčivo |
AR110995A1 (es) | 2017-02-24 | 2019-05-22 | Bayer Ag | Combinación de inhibidores de quinasa atr con sal de radio-223 |
CA3059534A1 (en) | 2017-05-11 | 2018-11-15 | Alpha Tau Medical Ltd. | Polymer coatings for brachytherapy devices |
CN111918699B (zh) | 2018-04-02 | 2024-03-08 | 阿尔法陶医疗有限公司 | 放射性核素的受控释放的装置 |
EP3563875A1 (en) * | 2018-05-04 | 2019-11-06 | Ceské vysoké ucení technické v Praze | Radium for radionuclide therapy, in combination with calcium metabolism affecting treatment |
LU100900B1 (de) * | 2018-08-10 | 2020-02-17 | Thomas Melchior Homann | Verbindungen zur modulation von a-ketoglutarsäure (2kg)-abhängigen oxygenasen |
FR3086186B1 (fr) * | 2018-09-26 | 2022-01-28 | Orano Med | Procede de production de plomb-212 a partir d'une solution aqueuse comprenant du thorium-228 et ses descendants |
FR3088769B1 (fr) * | 2018-11-15 | 2020-12-25 | Orano Med | Procede de preparation d'au moins un generateur a haute teneur en radium-228 |
US20220152228A1 (en) * | 2019-03-01 | 2022-05-19 | Washington University | Compositions and methods for radiotherapy using chelated radiotherapeutic agents and non-target tissue blockade |
RU2752845C1 (ru) * | 2020-05-13 | 2021-08-11 | Акционерное Общество "Наука И Инновации" | Способ получения высокочистого радия-223 |
CA3202211A1 (en) | 2020-12-16 | 2022-06-23 | Alpha Tau Medical Ltd. | Diffusing alpha-emitters radiation therapy with enhanced beta treatment |
CN113066598B (zh) * | 2021-03-25 | 2023-08-08 | 中国科学院近代物理研究所 | 一种从高能质子束辐照232Th靶引起的散裂反应中分离纯化223Ra的方法 |
US12070621B2 (en) | 2021-06-10 | 2024-08-27 | Alpha Tau Medical Ltd. | Diffusing alpha-emitter radiation therapy for pancreatic cancer |
US12070620B2 (en) | 2021-06-10 | 2024-08-27 | Alpha Tau Medical Ltd. | Activity levels for diffusing alpha-emitter radiation therapy |
US12076582B2 (en) | 2021-06-10 | 2024-09-03 | Alpha Tau Medical Ltd. | Diffusing alpha-emitter radiation therapy for colorectal cancer |
US12064643B2 (en) | 2021-06-10 | 2024-08-20 | Alpha Tau Medical Ltd. | Diffusing alpha-emitter radiation therapy for breast cancer |
US11964168B2 (en) | 2021-06-10 | 2024-04-23 | Alpha Tau Medical Ltd. | Diffusing alpha-emitter radiation therapy for prostate cancer |
US12076583B2 (en) | 2021-06-10 | 2024-09-03 | Alpha Tau Medical Ltd. | Diffusing alpha-emitter radiation therapy for melanoma |
US12042668B2 (en) | 2021-06-10 | 2024-07-23 | Alpha Tau Medical Ltd. | Diffusing alpha-emitter radiation therapy for squamous cell carcinoma |
US12076581B2 (en) | 2021-06-10 | 2024-09-03 | Alpha Tau Medical Ltd. | Diffusing alpha-emitter radiation therapy for glioblastoma |
AU2023221939A1 (en) | 2022-02-21 | 2024-08-22 | Bayer Healthcare Llc | System, method and device for delivery of a therapeutic or diagnostic agent |
WO2023159230A1 (en) | 2022-02-21 | 2023-08-24 | Bayer Healthcare Llc | System, method and device for delivery of a therapeutic or diagnostic agent |
CN115869658A (zh) * | 2022-12-29 | 2023-03-31 | 中国核动力研究设计院 | 用于制备Ra-223的分离系统及其分离方法、应用和制备方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH668489A5 (de) * | 1982-01-22 | 1988-12-30 | Vnii Mineralnogo Syrya | Radiometrisches verfahren zur bestimmung der konzentration natuerlicher radiumisotope und einrichtung zur durchfuehrung des verfahrens. |
AU626348B2 (en) * | 1988-10-14 | 1992-07-30 | Mallinckrodt, Inc. | Radiolabelled particulate composition |
US4970062A (en) * | 1989-05-30 | 1990-11-13 | The United States Of America As Represented By The United States Department Of Energy | Colloid labelled with radionuclide and method |
CA2123588A1 (en) * | 1991-11-14 | 1993-05-27 | Frederick C. Leung | Method for diagnosing and treating cancer |
IL109666A0 (en) * | 1993-05-17 | 1994-08-26 | Immunomedics Inc | A targeting composition containing a biotin- or avidinprotein conjugate and methods for the use thereof |
US5809394A (en) * | 1996-12-13 | 1998-09-15 | Battelle Memorial Institute | Methods of separating short half-life radionuclides from a mixture of radionuclides |
US6117413A (en) * | 1997-11-12 | 2000-09-12 | Battelle Memorial Institute | Radionuclide-binding compound, a radionuclide delivery system, a method of making a radium complexing compound, a method of extracting a radionuclide, and a method of delivering a radionuclide |
NO310544B1 (no) * | 1999-01-04 | 2001-07-23 | Algeta As | Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben |
NO314537B1 (no) * | 1999-12-06 | 2003-04-07 | Anticancer Therapeutic Inv Sa | Reseptorbindende konjugater |
NO312708B1 (no) * | 2000-02-21 | 2002-06-24 | Anticancer Therapeutic Inv Sa | Radioaktive liposomer til terapi |
NO313180B1 (no) * | 2000-07-04 | 2002-08-26 | Anticancer Therapeutic Inv Sa | Bensökende alfapartikkel emitterende radiofarmasöytika |
GB0213261D0 (en) * | 2002-06-10 | 2002-07-17 | Anticancer Therapeutic Inv Sa | Method |
US20060228297A1 (en) * | 2003-04-15 | 2006-10-12 | Roy Larsen | Thorium-227 for use in radiotherapy of soft tissue disease |
GB0308731D0 (en) * | 2003-04-15 | 2003-05-21 | Anticancer Therapeutic Inv Sa | Method of radiotherapy |
-
1999
- 1999-01-04 NO NO990001A patent/NO310544B1/no not_active IP Right Cessation
- 1999-12-17 IL IL14413599A patent/IL144135A0/xx not_active IP Right Cessation
- 1999-12-17 DK DK99960058T patent/DK1140212T3/da active
- 1999-12-17 MX MXPA01006823A patent/MXPA01006823A/es active IP Right Grant
- 1999-12-17 CA CA002358498A patent/CA2358498C/en not_active Expired - Lifetime
- 1999-12-17 TR TR2002/01442T patent/TR200201442T2/xx unknown
- 1999-12-17 EA EA200100642A patent/EA003496B1/ru not_active IP Right Cessation
- 1999-12-17 TR TR2002/01440T patent/TR200201440T2/xx unknown
- 1999-12-17 EP EP99960058A patent/EP1140212B1/en not_active Expired - Lifetime
- 1999-12-17 AU AU17004/00A patent/AU774991B2/en active Active
- 1999-12-17 CN CNB998161020A patent/CN1194764C/zh not_active Expired - Lifetime
- 1999-12-17 NZ NZ534618A patent/NZ534618A/xx not_active IP Right Cessation
- 1999-12-17 TR TR2001/02707T patent/TR200102707T2/xx unknown
- 1999-12-17 DE DE69932183T patent/DE69932183T2/de not_active Expired - Lifetime
- 1999-12-17 BR BR9916768-9A patent/BR9916768A/pt not_active Application Discontinuation
- 1999-12-17 AT AT99960058T patent/ATE331534T1/de active
- 1999-12-17 NZ NZ513135A patent/NZ513135A/en not_active IP Right Cessation
- 1999-12-17 CN CN2004100749238A patent/CN1767078B/zh not_active Expired - Lifetime
- 1999-12-17 PT PT99960058T patent/PT1140212E/pt unknown
- 1999-12-17 KR KR1020017008497A patent/KR100671387B1/ko active Protection Beyond IP Right Term
- 1999-12-17 ES ES99960058T patent/ES2268888T3/es not_active Expired - Lifetime
- 1999-12-17 NZ NZ545023A patent/NZ545023A/en not_active IP Right Cessation
- 1999-12-17 JP JP2000592029A patent/JP4649044B2/ja not_active Expired - Lifetime
- 1999-12-17 WO PCT/NO1999/000392 patent/WO2000040275A2/en active Search and Examination
-
2000
- 2000-01-03 US US09/476,569 patent/US6635234B1/en not_active Expired - Lifetime
-
2001
- 2001-07-02 ZA ZA200105431A patent/ZA200105431B/en unknown
-
2003
- 2003-06-12 US US10/459,941 patent/US20030206857A1/en not_active Abandoned
-
2006
- 2006-09-28 CY CY20061101404T patent/CY1105634T1/el unknown
- 2006-11-02 HK HK06112108.8A patent/HK1090750A1/xx not_active IP Right Cessation
-
2010
- 2010-04-20 JP JP2010096736A patent/JP5433490B2/ja not_active Expired - Lifetime
-
2014
- 2014-04-09 LU LU92425C patent/LU92425I2/fr unknown
- 2014-05-07 BE BE2014C028C patent/BE2014C028I2/fr unknown
- 2014-05-09 NO NO2014010C patent/NO2014010I1/no not_active IP Right Cessation
- 2014-05-13 CY CY2014020C patent/CY2014020I2/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100671387B1 (ko) | 석회화된 조직을 표적으로 하는, 통증 완화, 뼈 암 치료,및 뼈 표면 조절용 라듐-223의 제조 및 용도 | |
US7335154B2 (en) | Radiotherapy | |
Washiyama et al. | 227Th-EDTMP: A potential therapeutic agent for bone metastasis | |
US10596277B2 (en) | High purity therapeutic bone agents | |
Ando et al. | Production of 105Rh–EDTMP and its bone accumulation | |
US11813339B2 (en) | Method of use for therapeutic bone agents | |
NO317110B1 (no) | Nytt radiofarmasoytisk preparat | |
Srivastava et al. | Formulation for Tin-. sup. 117m/diethylenetriaminepentaacetic acids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20131218 Year of fee payment: 8 |
|
A101 | Application to extend term of patent right by permit | ||
FPAY | Annual fee payment |
Payment date: 20141218 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20160104 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20170102 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20180103 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20190103 Year of fee payment: 13 |